Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology

被引:0
|
作者
Hayashi, Toshinobu [1 ]
Yamamoto, Shun [2 ]
Miyata, Yoshiharu [3 ]
Takeda, Masayuki [4 ]
Abe, Masakazu [5 ]
Wada, Makoto [6 ]
Iino, Keiko [7 ]
Akechi, Tatsuo [8 ]
Imamura, Chiyo K. [9 ]
Okuyama, Ayako [10 ]
Ozawa, Keiko [11 ]
Kim, Yong-Il [12 ]
Sasaki, Hidenori [13 ]
Satomi, Eriko [14 ]
Tanaka, Ryuhei [15 ]
Nakajima, Takako Eguchi [16 ]
Nakamura, Naoki [17 ]
Nishimura, Junichi [18 ]
Noda, Mayumi [19 ]
Hayashi, Kazumi [20 ]
Higashi, Takahiro [21 ]
Boku, Narikazu [22 ]
Matsumoto, Koji [23 ]
Matsumoto, Yoko [24 ]
Okita, Kenji [25 ]
Yamamoto, Nobuyuki [26 ]
Aogi, Kenjiro [27 ]
Iihara, Hirotoshi [28 ]
机构
[1] Fukuoka Univ, Fac Pharmaceut Sci, Dept Emergency & Disaster Med Pharm, 8-19-1,Nanakuma,Jonan Ku, Fukuoka, Japan
[2] Natl Canc Ctr, Dept Head & Neck, Esophageal Med Oncol, Tokyo, Japan
[3] Kobe Univ, Dept Artificial Intelligence & Digital Hlth Sci, Grad Sch Med, 7-1-48 Minatojimaminamimachi,Chuo Ku, Kobe, Japan
[4] Nara Med Univ, Dept Epidemiol, 840 Shijo Cho, Kashihara, 6348521, Japan
[5] Hamamatsu Univ Sch Med, Dept Surg, 1-20-1 Handayama,Chuo Ku, Hamamatsu, Shizuoka 4313192, Japan
[6] Osaka Int Canc Inst, Dept Hematol, 3-1-69 Chuo Ku, Osaka, Osaka 5418567, Japan
[7] Natl Coll Nursing, Dept Adult Nursing, 1-2-1,Umezono, Kiyose, Tokyo 2048575, Japan
[8] Nagoya City Univ, Grad Sch Med Sci, Dept Psychiat & Cognit Behav Med, 1 Kawasumi,Mizuho Cho,Mizuho Ku, Nagoya 4678601, Japan
[9] Showa Univ, Adv Canc Translat Res Inst, 1-5-8 Hatanodai,Shinagawa Ku, Tokyo 1428555, Japan
[10] St Lukes Int Univ, Grad Sch Nursing Sci, 10-1 Akashi Cho,Chuo ku, Tokyo 1040044, Japan
[11] Natl Canc Ctr, Inst Canc Control, Div Survivorship, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan
[12] Yodogawa Christians Hosp, Div Med Oncol, 1-7-50 Kunijima,Higasiyodogawa Ku, Osaka, Osaka 5330024, Japan
[13] Fukuoka Univ, Div Med Oncol Hematol & Infect Dis, 7-45-1,Nanakuma,Jonan Ku, Fukuoka 8140180, Japan
[14] Natl Canc Ctr, Dept Palliat Med, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan
[15] Saitama Med Univ, Int Med Ctr, Dept Pediat Hematol & Oncol, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan
[16] Kyoto Univ, Grad Sch Med, Grad Sch Med, 54 Kawahara Cho,Shogoin,Sakyo ku, Kyoto 6068507, Japan
[17] St Marianna Univ, Dept Microbiol, 2-16-1,Sugao, Miyamae, Kawasaki 2168511, Japan
[18] Osaka Int Canc Inst, Dept Gastroenterol Surg, 3-1-69, Osaka 5418567, Japan
[19] Nonprofit Org Sasaeau KaiAlpha, 518-7 Kawado Cho,Chuo Ku, Chiba, Chiba 2600802, Japan
[20] Jikei Univ, Sch Med, Sch Med, Tokyo, Japan
[21] Univ Tokyo, Dept Hlth Serv Res, 7-3-1 Hongo,Bunkyo Ku, Tokyo 1130033, Japan
[22] Univ Tokyo, Inst Med Sci Hosp, Dept Oncol & Gen Med, 4-6-1 Shiroganedai,Minato ku, Tokyo 1088639, Japan
[23] Hyogo Canc Ctr, Div Diagnost Radiol, 13-70 Kitaoji Cho, Akashi, Hyogo 6730021, Japan
[24] Nonprofit Org Ehime Canc Support Orange No Kai, 3-8-24 Furukawaminami, Matsuyama, Ehime 7900943, Japan
[25] Otaru Ekisaikai Hosp, Dept Surg, 1-4-1 Inaho, Otaru, Hokkaido 0470032, Japan
[26] Wakayama Med Univ, Internal Med 3, 811-1 Kimiidera, Wakayama, 6418509, Japan
[27] Natl Hosp Org Shikoku Canc Ctr, Dept Breast Oncol, 160 Kou,Minamiumemoto Machi, Matsuyama, Ehime 7910280, Japan
[28] Gifu Univ Hosp, Dept Pharm, 1-1 Yanagido, Gifu 5011194, Japan
关键词
Antiemetics; Carboplatin; Chemotherapy-induced nausea and vomiting; Moderately emetogenic chemotherapy; Neurokinin-1 receptor antagonist; Systematic review and meta-analysis; DOUBLE-BLIND; BROAD RANGE; PHASE-II; APREPITANT; PREVENTION; EFFICACY; CANCER; DEXAMETHASONE; FOSAPREPITANT; PALONOSETRON;
D O I
10.1007/s10147-024-02623-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundChemotherapy-induced nausea and vomiting (CINV) commonly affects patient quality of life and the overall effectiveness of chemotherapy. This study aimed to evaluate whether adding neurokinin-1 receptor antagonists (NK1RAs) to 5-hydroxytryptamine-3 receptor antagonists (5-HT3RAs) and corticosteroids provides clinically meaningful benefits in preventing CINV in patients receiving moderately emetogenic chemotherapy (MEC).MethodsWe conducted a systematic review of PubMed, Cochrane Library, and Ichushi-Web to identify clinical studies evaluating NK1RAs combined with 5-HT3RAs and dexamethasone for managing CINV in MEC. The endpoints were complete response (CR), complete control (CC), total control (TC), adverse events, and costs. The data were analyzed using a random effects model.ResultsFrom 142 articles identified, 15 randomized controlled trials (RCTs), involving 4,405 patients, were included in the meta-analysis. Approximately 60% of the patients received carboplatin (CBDCA)-based chemotherapy. The meta-analysis showed that triplet antiemetic prophylaxis with NK1RA was significantly more effective for achieving CR than doublet prophylaxis in each phase. Regarding CC, the triplet antiemetic prophylaxis was significantly more effective than the doublet in the overall (risk difference [RD]: 0.11, 95% confidence interval [CI]: 0.06-0.17) and delayed (RD: 0.08, 95% CI: 0.02-0.13) phases. For TC, no significant differences were observed in any phase. Adding NK1RA did not cause adverse events.ConclusionsAdding NK1RA to CBDCA-based chemotherapy has shown clinical benefits. However, the clinical benefits of NK1RA-containing regimens for overall MEC have not yet been established and require RCTs that exclusively evaluate MEC regimens other than CBDCA-based chemotherapy.
引用
收藏
页码:1616 / 1631
页数:16
相关论文
共 50 条
  • [21] Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials
    Chow, Ronald
    Tsao, May
    Chiu, Leonard
    Popovic, Marko
    Milakovic, Milica
    Lam, Henry
    DeAngelis, Carlo
    ANNALS OF PALLIATIVE MEDICINE, 2018, 7 (02) : 221 - +
  • [22] Phase 2 Trial Results With the Novel Neurokinin-1 Receptor Antagonist Casopitant in Combination With Ondansetron and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy
    Arpornwirat, Wichit
    Albert, Istvan
    Hansen, Vincent L.
    Levin, Jeremey
    Bandekar, Rajesh R.
    Grunberg, Steven M.
    CANCER, 2009, 115 (24) : 5807 - 5816
  • [23] Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis
    Zhang, Zhonghan
    Zhang, Yaxiong
    Chen, Gang
    Hong, Shaodong
    Yang, Yunpeng
    Fang, Wenfeng
    Luo, Fan
    Chen, Xi
    Ma, Yuxiang
    Zhao, Yuanyuan
    Zhan, Jianhua
    Xue, Cong
    Hou, Xue
    Zhou, Ting
    Ma, Shuxiang
    Gao, Fangfang
    Huang, Yan
    Chen, Likun
    Zhou, Ningning
    Zhao, Hongyun
    Zhang, Li
    ONCOLOGIST, 2018, 23 (05): : 603 - 616
  • [24] Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis
    Alhifany, Abdullah A.
    McBride, Ali
    Almutairi, Abdulaali R.
    Cheema, Ejaz
    Shahbar, Alaa
    Alatawi, Yasser
    Alharbi, Adnan S.
    Babiker, Hani
    MacDonald, Karen
    Aapro, Matti
    Abraham, Ivo
    SUPPORTIVE CARE IN CANCER, 2020, 28 (03) : 1031 - 1039
  • [25] Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis
    Abdullah A. Alhifany
    Ali McBride
    Abdulaali R. Almutairi
    Ejaz Cheema
    Alaa Shahbar
    Yasser Alatawi
    Adnan S. Alharbi
    Hani Babiker
    Karen MacDonald
    Matti Aapro
    Ivo Abraham
    Supportive Care in Cancer, 2020, 28 : 1031 - 1039
  • [26] Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology
    Nakashima, Kazuhisa
    Harashima, Saki
    Kaneko, Rena
    Tanaka, Ryuhei
    Abe, Masakazu
    Wada, Makoto
    Iino, Keiko
    Akechi, Tatsuo
    Iihara, Hirotoshi
    Imamura, Chiyo K.
    Okuyama, Ayako
    Ozawa, Keiko
    Kim, Yong-il
    Satomi, Eriko
    Takeda, Masayuki
    Nakajima, Takako Eguchi
    Nakamura, Naoki
    Nishimura, Junichi
    Noda, Mayumi
    Hayashi, Kazumi
    Higashi, Takahiro
    Boku, Narikazu
    Matsumoto, Koji
    Matsumoto, Yoko
    Okita, Kenji
    Yamamoto, Nobuyuki
    Aogi, Kenjiro
    Sasaki, Hidenori
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (01) : 17 - 26
  • [27] Safety of clinical practice guideline-recommended antiemetic agents for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients: a systematic review and meta-analysis
    Patel, Priya
    Sing, Edric Paw Cho
    Dupuis, L. Lee
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (02) : 97 - 110
  • [28] Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting
    Thaiana Aragão Santana
    Damila Cristina Trufelli
    Leandro Luongo de Matos
    Felipe Melo Cruz
    Auro Del Giglio
    Supportive Care in Cancer, 2015, 23 : 213 - 222
  • [29] Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting
    Santana, Thaiana Aragao
    Trufelli, Damila Cristina
    de Matos, Leandro Luongo
    Cruz, Felipe Melo
    Del Giglio, Auro
    SUPPORTIVE CARE IN CANCER, 2015, 23 (01) : 213 - 222
  • [30] Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis
    Chow, Ronald
    Warr, David G.
    Navari, Rudolph M.
    Tsao, May
    Popovic, Marko
    Chiu, Leonard
    Milakovic, Milica
    Lam, Henry
    DeAngelis, Carlo
    SUPPORTIVE CARE IN CANCER, 2018, 26 (08) : 2519 - 2549